SPDR Portfolio S&P 400 Mid Cap ETF (DE:4JZ6) Price & Chart

Barclays analyst Richard Garchitorena upgraded Reliance (RS) to Overweight from Equal Weight with a price target of $507, up from $445. The firm upped the company’s 2027 and 2028 estimates

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

Mizuho raised the firm’s price target on Tenet Healthcare (THC) to $330 from $305 and keeps an Outperform rating on the shares. The firm upped targets in the acute care

ATI Inc. (($ATI)) has held its Q3 earnings call. Read on for the main highlights of the call. ATI delivered a strongly positive earnings call, highlighting broad year-over-year growth, record

Needham raised the firm’s price target on Liquidia (LQDA) to $66 from $58 and keeps a Buy rating on the shares. The company’s Q3 update “paints a more positive picture”

Priovant Therapeutics, a Roivant company, announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double-blind, placebo-controlled trial evaluating oral brepocitinib

BTIG analyst Julian Harrison raised the firm’s price target on Liquidia (LQDA) to $87 from $70 and keeps a Buy rating on the shares. Q3 results and October commercial metrics

Entegris (ENTG) announced that its Board of Directors has authorized a $500M share repurchase program and that the company expects to raise its quarterly cash dividend by 10% starting in

Entegris (ENTG) introduced an updated long-term financial model targeting a compound annual growth rate, CAGR, for revenue of approximately 15%, adjusted gross margin of approximately 55%, adjusted operating margin of